Physician profile
Enrique Serrano
NPI 1306437850
$1,228.59
in general payments reported to CMS, 2019-2025
10 companies · $27.39 in 2025
The $27.39 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $82.98 · 2023: $38.62 · 2024: $960 · 2025: $27.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $767 · Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $766.73 |
| Food and Beverage | $259.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $843.55 | 2024 | Iovera, Zilretta, Exparel |
| Samsung Hme America, INC. | $95.73 | 2024 | |
| Amgen INC. | $69.27 | 2021-2022 | |
| Innovation Technologies INC | $48.55 | 2022 | |
| Redhill Biopharma INC. | $44.77 | 2021 | |
| Ibsa Pharma INC. | $40.93 | 2023-2024 | Tirosint, Tirosint, Licart |
| Ermi LLC | $27.39 | 2025 | |
| Grt US Holding, INC. | $22.20 | 2021 | |
| Ucb, INC. | $18.60 | 2023 | Fintepla |
| Scilex Pharmaceuticals INC. | $17.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enrique Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.